Atara biotherapeutics announces second quarter 2021 financial results and operational progress

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2021, recent business highlights and key catalysts over the next several months. “we are very pleased with the progress achieved across all of our programs and important clinical u
ATRA Ratings Summary
ATRA Quant Ranking